Dr. David Weiner is Executive Vice President, Director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Research at The Wistar Institute. He is also Emeritus Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. In the lab, David and his colleagues are creating drugs using the same DNA codes and signals that our bodies use naturally. The drugs they are creating are natural compounds that can be given to people to prevent them from getting sick or to help them be healthier. One area of David’s research focuses on developing DNA vaccines to prevent illness. These DNA vaccines are designed to create specific proteins that trigger the immune system to respond to fight particular pathogens. David and his wife enjoy reading and going on walks with their dog Ruby. Ruby is a Shih Tzu Yorkie mix that they rescued after a recent hurricane in Puerto Rico. David received his B.S. in biology from the State University of New York at Stony Brook, his M.S. in biology from the University of Cincinnati, and his  Ph.D. in developmental biology from the University of Cincinnati College of Medicine. Afterwards, David worked as a research fellow in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania before joining the faculty there. He held a joint position as Assistant Professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine from 1990-1993. David returned to The Wistar Institute in 2016 to accept his current positions. Among his many awards and honors, David has been elected as a Fellow of the American Association for the Advancement of Science and the International Society for Vaccines. He has also received the NIH Director’s Transformative Research Award, the Vaccine Industry Excellence Award for Best Academic Research Team, the prestigious Hilleman Lectureship from the Children’s Hospital of Philadelphia, a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy, and the Scientific Achievement Award from Life Sciences Pennsylvania. In addition, David was named a "Top 20 Translational Researchers" in 2016 by Nature Biotechnology.